209917-48-6

Basic information

• Product Name: N-tert-Butyl 4-Aminophenylsulfonamide
• Synonyms: N-tert-Butyl 4-Aminophenylsulfonamide;4-Amino-N-(1,1-dimethylethyl)benzenesulfonamide;N-t-Butyl 4-aMinophenylsulfonaMide;N-tert-Butyl-4-aminobenzenesulfonamide
• CAS NO: 209917-48-6
• Molecular Formula: C₁₀H₁₆N₂O₂S
• Molecular Weight: 228.32
• EINECS: 1312995-182-4
• Product Categories: Acids and Derivatives;Amines and Anilines
• Mol File: 209917-48-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 374.8 °C at 760 mmHg
• Flash Point: 180.5 °C
• Appearance: /
• Density: 1.189 g/cm³
• Vapor Pressure: 8.11E-06mmHg at 25°C
• Refractive Index: 1.552
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 12.95±0.50(Predicted)
• CAS DataBase Reference: N-tert-Butyl 4-Aminophenylsulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-tert-Butyl 4-Aminophenylsulfonamide(209917-48-6)
• EPA Substance Registry System: N-tert-Butyl 4-Aminophenylsulfonamide(209917-48-6)

Safety Data

• Hazardous Substances Data: 209917-48-6(Hazardous Substances Data)

Usage

Description

N-tert-Butyl 4-Aminophenylsulfonamide is a synthetic intermediate with significant applications in the pharmaceutical industry. It is characterized by its chemical structure that allows for the creation of various pharmaceutical products, particularly CK2 and PIM kinase inhibitors.

Uses

Used in Pharmaceutical Industry:
N-tert-Butyl 4-Aminophenylsulfonamide is used as a synthetic intermediate for the development of pharmaceutical products. Its primary application is in the synthesis of CK2 and PIM kinase inhibitors, which are crucial in the treatment of various diseases and conditions. The compound's unique structure enables the creation of these inhibitors, making it a valuable asset in the pharmaceutical field.

InChI:InChI=1/C10H16N2O2S/c1-10(2,3)12-15(13,14)9-6-4-8(11)5-7-9/h4-7,12H,11H2,1-3H3

Upstream product

• 103-84-4 Acetanilid 
• 121-60-8 p-acetylaminobenzenesulfonyl chloride 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 294885-56-6 N-(4-(N-(tert-butyl)sulfamoyl)phenyl)acetamide 
• 49690-09-7 N-dimethylethyl-4-nitrobenzenesulfonamide 

Downstream Products

• 608523-50-8 6-[4-(tert-Butylsulfamoyl)phenylazo]-pyridoxal-5-phosphate 
• 1028253-30-6 3-methyl-N-(4-sulfamoylphenyl)-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 1028253-28-2 N-(4-(tert-butylsulfamoyl)phenyl)-3-methyl-D-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 1028253-27-1 N-(4-(tert-butylsulfamoyl)phenyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 915006-33-6 4-cyano-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylic acid [4-tert-butylsulfamoyl-2-(4,4-dimethyl-cyclohex-1-enyl)-phenyl]-amide 
• 915006-34-7 4-amino-N-tert-butyl-3-(4,4-dimethyl-cyclohex-1-enyl)-benzenesulfonamide 
• 1028253-29-3 2-(4-(N-tert-butylsulfamoyl)phenylamino)-3,3-dimethylbutanoic acid 
• 499777-85-4 1-(tert-butylaminosulfonylphenyl)-4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazole 
• 499777-84-3 1-(tert-butylaminosulfonylphenyl)-5-(3-fluoro-4-methoxyphenyl)imidazole 
• 265114-23-6 cimicoxib 
• 915006-43-8 4-amino-3-bromo-N-tert-butyl-benzenesulfonamide 

Relevant articles and documents

Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold

Recent reports have highlighted the dual bromodomains of TAF1 (TAF1(1,2)) as synergistic with BET inhibition in cellular cancer models, engendering interest in TAF/BET polypharmacology. Here, we examine structure activity relationships within the BI-2536 PLK1 kinase inhibitor scaffold, previously reported to bind BRD4. We examine binding by this ligand to TAF1(2) and apply structure guided design strategies to discriminate binding to both the PLK1 kinase and BRD4(1) bromodomain while retaining activity on TAF1(2). Through this effort we discover potent dual inhibitors of TAF1(2)/BRD4(1), as well as biased derivatives showing marked TAF1 selectivity. We resolve X-ray crystallographic data sets to examine the mechanisms of the observed TAF1 selectivity and to provide a resource for further development of this scaffold.

USP30 INHIBITORS

The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mitochondrial defects including neurodegenerative diseases such as Alzheimer's and Parkinson's or a neoplastic disease such as leukemia.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.